- Home
- PTA vs ARQT Comparison
PTA vs ARQT Comparison
Compare PTA & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTA
- ARQT
- Stock Information
- Founded
- PTA 2020
- ARQT 2016
- Country
- PTA United States
- ARQT United States
- Employees
- PTA N/A
- ARQT N/A
- Industry
- PTA Trusts Except Educational Religious and Charitable
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- PTA Finance
- ARQT Health Care
- Exchange
- PTA Nasdaq
- ARQT Nasdaq
- Market Cap
- PTA 1.1B
- ARQT 1.1B
- IPO Year
- PTA N/A
- ARQT 2020
- Fundamental
- Price
- PTA $19.91
- ARQT $13.08
- Analyst Decision
- PTA
- ARQT Strong Buy
- Analyst Count
- PTA 0
- ARQT 5
- Target Price
- PTA N/A
- ARQT $17.00
- AVG Volume (30 Days)
- PTA 159.2K
- ARQT 1.9M
- Earning Date
- PTA 01-01-0001
- ARQT 02-25-2025
- Dividend Yield
- PTA 8.31%
- ARQT N/A
- EPS Growth
- PTA N/A
- ARQT N/A
- EPS
- PTA N/A
- ARQT N/A
- Revenue
- PTA N/A
- ARQT $138,708,000.00
- Revenue This Year
- PTA N/A
- ARQT $215.24
- Revenue Next Year
- PTA N/A
- ARQT $53.63
- P/E Ratio
- PTA N/A
- ARQT N/A
- Revenue Growth
- PTA N/A
- ARQT 182.84
- 52 Week Low
- PTA $15.84
- ARQT $5.38
- 52 Week High
- PTA $19.67
- ARQT $16.20
- Technical
- Relative Strength Index (RSI)
- PTA 60.79
- ARQT 41.94
- Support Level
- PTA $19.52
- ARQT $13.33
- Resistance Level
- PTA $20.09
- ARQT $15.09
- Average True Range (ATR)
- PTA 0.17
- ARQT 0.86
- MACD
- PTA 0.06
- ARQT -0.16
- Stochastic Oscillator
- PTA 84.09
- ARQT 6.25
About PTA Cohen & Steers Tax-Advantaged Preferred Securities and Income Fund of Beneficial Interest
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its primary investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.